The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Sarcopenia Treatment Global Market Report 2024, the sarcopenia treatment market is expected to show promising growth in the forecast period.

Market Overview

• Strong Growth: The sarcopenia treatment market has shown significant growth, increasing from $3.30 billion in 2023 to $3.52 billion in 2024 at a CAGR of 6.6%.
• Future Projections: Expected to reach $4.44 billion by 2028, growing at a CAGR of 6.0%.

Factors Driving Growth

• Aging Population: An increase in the elderly population leads to a higher prevalence of sarcopenia.
• Awareness and Diagnosis: Improved recognition and diagnosis of the condition have contributed to market growth.
• Lifestyle Changes: Sedentary lifestyles and poor dietary habits increase the risk of sarcopenia.
• Public Health Initiatives: Government and healthcare organizations are actively promoting interventions to manage sarcopenia.
• Regulatory Approvals: Approval of new treatments and therapies boosts market expansion.

Future Growth Drivers

• Personalized Medicine: Tailored treatment plans improve patient outcomes.
• Nutritional Interventions: Enhanced focus on diet and supplements to combat sarcopenia.
• Digital Health Platforms: Integration of technology for better patient management.
• Patient Education and Empowerment: Increased awareness and self-management strategies.
• Global Health Initiatives: International efforts to address sarcopenia and related health issues.

View More On The Sarcopenia Treatment Market Report 2024 – https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

Emerging Trends

• Personalized Therapies: Customized treatment options are becoming more prevalent.
• Novel Drug Classes: Development of new medications specifically targeting sarcopenia.
• Digital Health Integration: Use of apps and wearables to monitor and manage the condition.
• Collaborative Research Initiatives: Joint efforts between companies and research institutions.
• Research and Development: Continuous innovation in treatment methods.

Impact of Malnutrition

• Global Challenge: Malnutrition, including both undernutrition and obesity, exacerbates sarcopenia.
• WHO Report: As of 2022, malnutrition affects millions globally, highlighting the need for effective sarcopenia treatments.
• Interventions: Nutritional therapy and exercise are key in improving muscle mass and strength.

Key Players

• Major Companies: Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company.
• Others: BASF SE, Nestle Health Science, Haleon Group, Regeneron Pharmaceuticals Inc., DSM, Amway, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill.

Notable Developments

• Biophytis FDA Authorization: In September 2023, Biophytis received FDA approval for the SARA-31 Phase 3 study to evaluate Sarconeos (BIO101) in sarcopenia treatment.
  • Study Details: Involves around 900 patients aged over 65, focusing on mobility disability, walking speed, hand grip strength, and quality of life.

Strategic Acquisitions

• Rejuveron Life Sciences AG: Acquired Rejuvenate Biomed NV for $16.99 million in October 2021 to accelerate clinical progress in sarcopenia therapeutics.
  • Focus: Development of RJx-01 for both acute and chronic sarcopenia.

Market Segmentation

• By Treatment Type: Protein supplements, Vitamin B12 supplements, Vitamin D and Calcium supplements, other treatments.
• By Type: Primary sarcopenia, secondary sarcopenia.
• By Route of Administration: Oral, parenteral, enteral.
• By Distribution Channel: Hospital pharmacies, retail pharmacies, online pharmacies, other channels.

Regional Insights

• North America: The largest market in 2023.
• Asia-Pacific: Expected to be the fastest-growing region in the forecast period.

Conclusion

The sarcopenia treatment market is poised for robust growth, driven by an aging population, increasing awareness, and innovative treatment approaches. With significant advancements and strategic initiatives by key players, the market is set to expand further, offering improved outcomes for those affected by sarcopenia.

Request A Sample Of The Global Sarcopenia Treatment Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=13926&type=smp